Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $262.6 million.

  • United Therapeutics' Other Non-Current Assets rose 4302.83% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 4302.83%. This contributed to the annual value of $222.1 million for FY2024, which is 4631.09% up from last year.
  • Latest data reveals that United Therapeutics reported Other Non-Current Assets of $262.6 million as of Q3 2025, which was up 4302.83% from $233.3 million recorded in Q2 2025.
  • United Therapeutics' Other Non-Current Assets' 5-year high stood at $262.6 million during Q3 2025, with a 5-year trough of $105.8 million in Q2 2022.
  • Moreover, its 5-year median value for Other Non-Current Assets was $151.8 million (2023), whereas its average is $159.4 million.
  • As far as peak fluctuations go, United Therapeutics' Other Non-Current Assets crashed by 4022.6% in 2022, and later soared by 4631.09% in 2024.
  • Quarter analysis of 5 years shows United Therapeutics' Other Non-Current Assets stood at $108.2 million in 2021, then rose by 5.64% to $114.3 million in 2022, then soared by 32.81% to $151.8 million in 2023, then soared by 46.31% to $222.1 million in 2024, then increased by 18.24% to $262.6 million in 2025.
  • Its last three reported values are $262.6 million in Q3 2025, $233.3 million for Q2 2025, and $222.4 million during Q1 2025.